Zacks Investment Research
14 Aug 2026, 22:41 UTC · 2h ago
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
14 Aug 2026, 22:41 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Vivos Therapeutics reported a quarterly loss of $0.31 per share, beating the Zacks Consensus Estimate of a $0.42 loss. — An earnings beat, particularly a smaller loss than expected, typically provides a short-term positive catalyst for a stock's price.
+0.30Vivos Therapeutics reported quarterly revenues of $5.15 million, missing the Zacks Consensus Estimate by 5.15%. — Missing revenue expectations suggests slowing growth or operational headwinds, which usually pressures the share price.
-0.20Vivos Therapeutics shares have declined approximately 85% since the beginning of the year. — Extreme year-to-date underperformance indicates severe lack of investor confidence and high volatility risk.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company reported an earnings surprise with a smaller loss than estimated, although revenue missed estimates and the stock has significantly underperformed the market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
